Conv. Plasma
Nigella Sativa

All tixagevimab/cilgavimab..
Meta analysis
study COVID-19 treatment researchTixagevimab/cilgavimabTixagev../c.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 86% Improvement Relative Risk Symp. case 76% Tixagevimab/c..  PROVENT  Prophylaxis  DB RCT Is prophylaxis with tixagevimab/cilgavimab beneficial for COVID-19? Double-blind RCT 5,172 patients in multiple countries Fewer symptomatic cases with tixagevimab/cilgavimab (p=0.00046) Levin et al., Open Forum Infectious Di.., Dec 2021 Favors tixagevimab/ci.. Favors control

PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults

Levin et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab466.1646, PROVENT, NCT04625725
Dec 2021  
  Source   PDF   All   Meta
36th treatment shown to reduce risk in May 2022
*, now known with p = 0.00002 from 15 studies, recognized in 30 countries. Efficacy is variant dependent.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
PrEP RCT with 3,441 tixagevimab/cilgavimab patients and 1,731 control patients, showing lower risk of symptomatic cases with treatment. Followup data is from
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.1 Planas, BA.5, BA.2.75, XBB Haars, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.1 Pochtovyi.
risk of death, 85.7% lower, RR 0.14, p = 0.11, treatment 0 of 3,441 (0.0%), control 2 of 1,731 (0.1%), NNT 866, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of symptomatic case, 76.3% lower, RR 0.24, p < 0.001, treatment 8 of 3,441 (0.2%), control 17 of 1,731 (1.0%), NNT 133.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Levin et al., 8 Dec 2021, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, preprint, 19 authors, trial NCT04625725 (history) (PROVENT).
This PaperTixagev../c..All
Abstract: LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/ Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults Myron J. Levin, MD1; Andrew Ustianowski, MBBS2; Stéphane De Wit, MD3; Odile Launay, MD, PhD4; Miles Avila, MPH, GStat5; Seth Seegobin, PhD5; Alison Templeton, PhD5; Yuan Yuan, PhD6; Philip Ambery, FRCP5; Rosalinda H. Arends, PhD5; Rohini Beavon, PhD5; Karen A. Near, MD5; Kelly W. Padilla, PharmD5; Konstantina Psachoulia, PhD5; Audrey Sharbaugh, PhD5; Katie Streicher, PhD5; Menelas N. Pangalos, PhD5; Mark T. Esser, PhD5; Robert A. Gasser, Jr., MD5; 1University of Colorado Anschutz Medical Campus, Aurora, CO; 2North Manchester General Hospital, Manchester, England, United Kingdom; 3CHU St-Pierre, Brussels, Brussels Hoofdstedelijk Gewest, Belgium; 4Université de Paris, Inserm F-CRIN I-REIVAC, Paris, Ile-de-France, France; 5AstraZeneca, Gaithersburg, Maryland; 6AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, Maryland Session: 55. Late Breaker Abstracts: COVID-19 Treatment & Prophylaxis Thursday, September 30, 2021: 6:15 PM Background. Vaccines effectively prevent COVID-19, but some individuals have medical comorbidities or receive therapies that impair their immune response to vaccination, or are ineligible for vaccination. For such individuals who remain at risk of COVID-19, monoclonal antibodies may provide additional rapid protection. AZD7442 comprises 2 fully human extended half-life SARS-CoV-2–neutralizing antibodies that bind distinct epitopes of the viral spike protein receptor binding domain. AZD7442 is in development for the prevention and treatment of COVID-19. Here, we report primary Phase 3 study results of AZD7442 for pre-exposure prophylaxis of symptomatic COVID-19. Methods. PROVENT (NCT04625725) is a Phase 3, 2:1 randomized, double-blind, placebo-controlled study of a single 300-mg AZD7442 dose (2 intramuscular injections; 150 mg each of tixagevimab and cilgavimab) for symptomatic COVID-19 prevention. Participants were unvaccinated adults (≥ 18 years old) without prior SARS-CoV-2 infection, who may benefit from immunoprophylaxis with antibodies due to an increased risk of either inadequate response to vaccination or SARS-CoV-2 exposure. The primary study endpoints were first case of SARS-CoV-2 RT-PCR-positive symptomatic illness post dose and prior to Day 183 (efficacy), and safety of AZD7442. Results. In total, 5197 participants (mean age 53.5 years, 46% female) were randomized and dosed (safety analysis set): AZD7442 n=3460; placebo n=1737. In the primary efficacy analysis (full pre-exposure analysis set, n=5172), AZD7442 reduced the risk of developing symptomatic COVID-19 by 77% (95% confidence interval S810 • OFID 2021:8 (Suppl 1) • Late Breaking Abstracts 46.0, 90.0) vs placebo (P< 0.001) (Table). Adverse events occurred in 35% and 34% of participants administered AZD7442 and placebo, respectively, and injection site reactions occurred in 2.4% and 2.1% of participants, respectively (safety analysis set). There was 1 case of severe/critical COVID-19 and 2 COVID-19–related deaths in the placebo arm. Conclusion. The primary study endpoints were met: a one-time dose of AZD7442 demonstrated statistically significant protection against symptomatic COVID-19 and was well tolerated. AZD7442 is the first long-acting monoclonal antibody combination that represents a potential new option to augment COVID-19 prevention. PROVENT funding statement image Disclosures. Myron J. Levin, MD, GSK..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop